Cediranib: Difference between revisions
Content deleted Content added
m Reverted edits by Fvasconcellos (talk) to last version by DAJF |
|||
| Line 1: | Line 1: | ||
{{drugbox | |
|||
#REDIRECT [[Cediranib]] |
|||
| IUPAC_name = 4-[(4-fluoro-2-methyl-1''H''-indol-5-yl)oxy]-6-methoxy-<br>7-[3-(pyrrolidin-1-yl)propoxy]quinazoline |
|||
| image = AZD2171.svg |
|||
| width = 250px |
|||
| CAS_number = |
|||
| ATC_prefix = |
|||
| ATC_suffix = |
|||
| PubChem = |
|||
| DrugBank = |
|||
| C = 25 | H = 27 | F = 1 | N = 4 | O = 3 |
|||
| molecular_weight = 450.5 g/mol |
|||
| bioavailability = |
|||
| protein_bound = |
|||
| metabolism = |
|||
| elimination_half-life = 12 to 35 hours |
|||
| excretion = |
|||
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|||
| pregnancy_US = <!-- A / B / C / D / X --> |
|||
| pregnancy_category = |
|||
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S8 --> |
|||
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> |
|||
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> |
|||
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|||
| legal_status = |
|||
| routes_of_administration = Oral |
|||
}} |
|||
'''Cediranib''' (tentative trade name '''Recentin'''), also known as AZD2171, is a potent [[kinase inhibitor|inhibitor]] of [[vascular endothelial growth factor]] (VEGF) receptor [[tyrosine kinase]]s. It is being developed by [[AstraZeneca]] as a possible chemotherapeutic agent for oral administration. |
|||
As of 2007, it is undergoing [[Clinical trial#Phase I|Phase I]] [[clinical trial]]s for the treatment of [[Lung cancer#Non-small cell lung cancer|non-small cell]] [[lung cancer]] and [[colorectal cancer]] in adults, as well as tumors of the [[central nervous system]] in children. |
|||
==Further reading== |
|||
*{{cite journal |author=Wedge S, Kendrew J, Hennequin L ''et al''. |title=AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer |journal=Cancer Res |volume=65 |issue=10 |pages=4389–400 |year=2005 |pmid=15899831}} |
|||
==External links== |
|||
*[http://www.cancerline.com/cancerlinehcp/15602_15632_9_3_1.aspx AZD2171—AstraZeneca Pipeline] |
|||
{{Chemotherapeutic agents}} |
|||
{{pharma-stub}} |
|||
[[Category:Tyrosine kinase inhibitors]] |
|||
Revision as of 13:29, 21 December 2007
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| Pharmacokinetic data | |
| Elimination half-life | 12 to 35 hours |
| Identifiers | |
| |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.196.628 |
| Chemical and physical data | |
| Formula | C25H27FN4O3 |
| Molar mass | 450.5 g/mol g·mol−1 |
Cediranib (tentative trade name Recentin), also known as AZD2171, is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases. It is being developed by AstraZeneca as a possible chemotherapeutic agent for oral administration.
As of 2007, it is undergoing Phase I clinical trials for the treatment of non-small cell lung cancer and colorectal cancer in adults, as well as tumors of the central nervous system in children.
Further reading
- Wedge S, Kendrew J, Hennequin L; et al. (2005). "AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer". Cancer Res. 65 (10): 4389–400. PMID 15899831.
{{cite journal}}: Explicit use of et al. in:|author=(help)CS1 maint: multiple names: authors list (link)
External links
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |